Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma
NCT00725400 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450
Last updated 2011-07-20
Summary
RATIONALE: Monoclonal antibodies, such as Cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.This is an anti-cancer drug which has already been approved by the FDA for use in patients who have Colorectal Cancer. Cetuximab can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation Therapy uses high-energy x-rays to kill tumor cells and cause less damage to normal tissue . Giving the drug Cetuximab together with Radiation Therapy may kill more tumor cells. Surgery is the most common treatment for Colorectal Cancer to remove the tumor, as well as a small margin of surrounding normal tissue and possibly nearby lymph nodes. Surgery is usually used in conjunction with other conventional treatments such as Radiation Therapy. Radiation Therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation Therapy after surgery may kill any tumor cells that remain after surgery.
Screening test such as Fecal Occult Blood Test (FOBT) and Colonoscopy has to be done. Tumor markers for Colorectal Carcinoma are Carcinoembryonic antigen (CAE) and CA 19-9 and to assess the response of tumor markers Carcinoembryonic antigen (CAE) and CA 19-9 will be used and periodically Colonoscopy has to be done. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation.
PURPOSE: Determine the tumor response rate treated with Cetuximab and Radiation Therapy Vs Surgery before or after Radiation Therapy in patients with Colorectal Cancer from stage II to IV
Conditions
- Colorectal Carcinoma
Interventions
- OTHER
-
Cetuximab and Radiation Therapy
Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
- PROCEDURE
-
Surgery and Radiation Therapy
Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
Sponsors & Collaborators
- collaborator INDUSTRY
- collaborator INDUSTRY
-
American Scitech International
lead OTHER
Principal Investigators
-
Ratna Grewal, MD · American Scitech International- eCRO
-
Prem A Nandiwada, MD · Raritan Bay Medical Center
-
Sarat Babu, MD · St. Peter's Hospital
-
S N Agrawal, MD · JLR Hospital in India
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-02-28
- Primary Completion
- 2014-02-28
- Completion
- 2014-02-28
Countries
- United States
Study Locations
More Related Trials
-
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
NCT00020930 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
NCT00079066 ·Status: COMPLETED ·Phase: PHASE3
-
Pre-op Rectal ChemoRad +/- Cetuximab
NCT00527111 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
NCT00611858 ·Status: TERMINATED ·Phase: PHASE2
-
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
NCT00571740 ·Status: WITHDRAWN ·Phase: PHASE2
-
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
NCT00686166 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
NCT00538291 ·Status: TERMINATED ·Phase: PHASE2
-
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
NCT00766142 ·Status: TERMINATED ·Phase: PHASE2
-
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
NCT02630420 ·Status: WITHDRAWN ·Phase: PHASE1
-
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
NCT02117466 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
NCT00954876 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
NCT01126450 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
NCT00063141 ·Status: COMPLETED ·Phase: PHASE3
-
First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
NCT00251186 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
NCT00640081 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
NCT00208546 ·Status: COMPLETED ·Phase: PHASE3
-
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
NCT01287130 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
NCT00081224 ·Status: TERMINATED ·Phase: PHASE2
-
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
NCT01004159 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
NCT02110082 ·Status: COMPLETED ·Phase: PHASE1
-
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
NCT02164916 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
NCT00336856 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer
NCT00383695 ·Status: UNKNOWN ·Phase: PHASE2
-
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT02713373 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
NCT00326495 ·Status: COMPLETED ·Phase: PHASE2